Trials / Completed
CompletedNCT06068673
The Potential Impact of Clindamycin on Neurosurgery Patients.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Damanhour University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A prospective, open-label, single center, controlled trial. 44 patients that underwent neurosurgery or presented meningitis signs, for whom Clindamycin add-on therapy to assess its effect on neurological complication in relation to Neuron-specific enolase (NSE) and Neurotensin biomarkers levels.
Detailed description
1. This is a prospective, open-label, single center, controlled trial. 44 patients that underwent neurosurgery or presented meningitis signs, for whom Clindamycin add-on therapy is prescribed (900 - 1200 mg twice daily) will be recruited from Alexandria University Main Hospital. 2. Whole blood samples will be collected for Analyses of Neuron-specific enolase (NSE) and Neurotensin will be detected by ELISA. 3. All patients will be assessed for complete blood count (CBC), kidney function, liver function, Methodology * Patients will be enrolled if they underwent surgery or presented with clinical signs of meningitis. * All enrolled 44 patients will be divided into two groups; Group I are patients who will receive clindamycin added-on therapy. Group II patients will be managed with the standard regimen. * Complete physical, laboratory, and radiological assessment will be done for all patients * All patients will be followed up during 2 weeks period. * Serum samples will be collected for measuring the biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clindamycin 600 mg | Clindamycin 900 - 1200 mg TWICE per day during 2 weeks period. |
| DRUG | standard regimen | standard regimen |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-30
- First posted
- 2023-10-05
- Last updated
- 2024-01-19
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06068673. Inclusion in this directory is not an endorsement.